Computational inhibitor design against malaria plasmepsins

被引:41
作者
Bjelic, S.
Nervall, M.
Gutierrez-de-Teran, H.
Ersmark, K.
Hallberg, A.
Aqvist, J.
机构
[1] Uppsala Univ, Ctr Biomed, Dept Cell & Mol Biol, SE-75124 Uppsala, Sweden
[2] Uppsala Univ, Ctr Biomed, Dept Med Chem, SE-75123 Uppsala, Sweden
关键词
malaria; plasmepsin; inhibitor design; reaction mechanism; molecular dynamics; linear interaction energy method;
D O I
10.1007/s00018-007-7102-2
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Plasmepsins are aspartic proteases involved in the degradation of the host cell hemoglobin that is used as a food source by the malaria parasite. Plasmepsins are highly promising as drug targets, especially when combined with the inhibition of falcipains that are also involved in hemoglobin catabolism. In this review, we discuss the mechanism of plasmepsins I-IV in view of the interest in transition state mimetics as potential compounds for lead development. Inhibitor development against plasmepsin II as well as relevant crystal structures are summarized in order to give an overview of the field. Application of computational techniques, especially binding affinity prediction by the linear interaction energy method, in the development of malarial plasmepsin inhibitors has been highly successful and is discussed in detail. Homology modeling and molecular docking have been useful in the current inhibitor design project, and the combination of such methods with binding free energy calculations is analyzed.
引用
收藏
页码:2285 / 2305
页数:21
相关论文
共 102 条
[1]   Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children:: single-blind extended follow-up of a randomised controlled trial [J].
Alonso, PL ;
Sacarlal, J ;
Aponte, JJ ;
Leach, A ;
Macete, E ;
Aide, P ;
Sigauque, B ;
Milman, J ;
Mandomando, I ;
Bassat, Q ;
Guinovart, C ;
Espasa, M ;
Corachan, S ;
Lievens, M ;
Navia, MM ;
Dubois, MC ;
Menendez, C ;
Dubovsky, F ;
Cohen, J ;
Thompson, R ;
Ballou, WR .
LANCET, 2005, 366 (9502) :2012-2018
[2]   Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children:: randomised controlled trial [J].
Alonso, PL ;
Sacarlal, J ;
Aponte, JJ ;
Leach, A ;
Macete, E ;
Milman, J ;
Mandomando, I ;
Spiessens, B ;
Guinovart, C ;
Espasa, M ;
Bassat, Q ;
Aide, P ;
Ofori-Anyinam, O ;
Navia, MM ;
Corachan, S ;
Ceuppens, M ;
Dubois, MC ;
Demoitié, MA ;
Dubovsky, F ;
Menéndez, C ;
Tornieporth, N ;
Ballou, WR ;
Thompson, R ;
Cohen, J .
LANCET, 2004, 364 (9443) :1411-1420
[3]   Ligand binding affinities from MD simulations [J].
Åqvist, J ;
Luzhkov, VB ;
Brandsdal, BO .
ACCOUNTS OF CHEMICAL RESEARCH, 2002, 35 (06) :358-365
[4]  
Åqvist J, 2001, COMB CHEM HIGH T SCR, V4, P613
[5]   NEW METHOD FOR PREDICTING BINDING-AFFINITY IN COMPUTER-AIDED DRUG DESIGN [J].
AQVIST, J ;
MEDINA, C ;
SAMUELSSON, JE .
PROTEIN ENGINEERING, 1994, 7 (03) :385-391
[6]   On the validity of electrostatic linear response in polar solvents [J].
Aqvist, J ;
Hansson, T .
JOURNAL OF PHYSICAL CHEMISTRY, 1996, 100 (22) :9512-9521
[7]   SIMULATION OF ENZYME-REACTIONS USING VALENCE-BOND FORCE-FIELDS AND OTHER HYBRID QUANTUM-CLASSICAL APPROACHES [J].
AQVIST, J ;
WARSHEL, A .
CHEMICAL REVIEWS, 1993, 93 (07) :2523-2544
[8]   Novel uncomplexed and complexed structures of plasmepsin II, an aspartic protease from Plasmodium falciparum [J].
Asojo, OA ;
Gulnik, SV ;
Afonina, E ;
Yu, B ;
Ellman, JA ;
Haque, TS ;
Silva, AM .
JOURNAL OF MOLECULAR BIOLOGY, 2003, 327 (01) :173-181
[9]   Structures of Ser205 mutant plasmepsin II from Plasmodium falciparum at 1.8 Å in complex with the inhibitors rs367 and rs370 [J].
Asojo, OA ;
Afonina, E ;
Gulnik, SV ;
Yu, B ;
Erickson, JW ;
Randad, R ;
Medjahed, D ;
Silva, AM .
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2002, 58 :2001-2008
[10]   Drug therapy: Effectiveness of antimalarial drugs [J].
Baird, JK .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (15) :1565-1577